Journal article
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
Abstract
Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral anticoagulants (NOACs) were compared with warfarin in large randomized trials for the prevention of stroke and systemic embolism. Today's clinician is faced with the difficult task of selecting a suitable OAC for a patient with a particular clinical profile or a …
Authors
Diener H-C; Aisenberg J; Ansell J; Atar D; Breithardt G; Eikelboom J; Ezekowitz MD; Granger CB; Halperin JL; Hohnloser SH
Journal
European Heart Journal, Vol. 38, No. 12, pp. 852–859
Publisher
Oxford University Press (OUP)
Publication Date
March 21, 2017
DOI
10.1093/eurheartj/ehv643
ISSN
0195-668X
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, OralAnticoagulantsAtrial FibrillationCardiac Resynchronization TherapyCatheter AblationClinical Decision-MakingContraindications, DrugCoronary Artery DiseaseDrug Administration ScheduleElectric CountershockHeart Valve DiseasesHeart Valve ProsthesisHumansPercutaneous Coronary InterventionPeripheral Arterial DiseaseRandomized Controlled Trials as TopicRisk FactorsStentsStroke